Widecells Group Plc (LON:WDC) CEO João Andrade and CSO Prof Peter Hollands talk to DirectorsTalk about being awarded a licence from the Human Tissue Authority, what it means for the group, how the services differ from competitors, the revenue model for BabyCells, marketing and other advances we can expect.
Following its HTA Research Licence granted in July 2017, WideCells Ltd has now been granted a Human Application Licence, number 22665, to import, export, process, store and distribute for treatment umbilical cord blood and umbilical cord tissue within the UK and within other EU member states. Accordingly, the Group is now able to launch its BabyCells service, which offers umbilical cord blood and tissue storage, including processing and distribution for treatment. To support roll-out, the group will actively look for agents, initially focussing on Europe, to promote its stem cell storage services. It will provide agents with services including marketing, training, custom designed collection devices, software maintenance and technical support. Additionally, the company offers agents the added benefits of support from CellPlan and Wideacademy; Wideacademy will provide educational and training services to agents and raise awareness of the potential benefits of stem cell treatment to potential storage clients whilst CellPlan will provide financial cover to ensure stem cell treatment is accessible and affordable.
Going forward, the group intends to add additional stem cell services such as dental pulp processing and storage (TeethCells) and Adipose tissue collection, processing and storage (LipoCells) to increase the Group’s stem cell storage product offering.